A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa

Sponsor
University Medical Center Groningen
Study ID
NCT01704534
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Ustekinumab — DRUG
    subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28

Study Details

The purpose of this study is to determine whether ustekinumab is effective in the treatment of moderate to severe hidradenitis suppurativa.

Key Dates

Start date
May 31, 2012
Status verified
Apr 2024
Primary completion
Jan 31, 2014
Completion
Apr 30, 2014

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ustekinumab
    Ustekinumab 45 mg or 90 mg (dependent on patient's weight) administered on weeks 0-4-16-28

Primary Outcome Measure

Change in Sartorius score [ Time Frame: 76 weeks ]

Related Studies